RxDoctor Payments DataLook up a doctor →

Tiffany Fonte, DO

Cardiovascular Disease · Henderson, NVNPI 1255779443

Payments from drug & device makers

$17,821in general payments, 2019–2025

Across 504 payments — averaging $35.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$2K
  • Abiomed$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Boston Scientific$777
  • plus $8K from 43 others

What the payments were for

  • Travel & lodging$1,5229%
  • Food & beverage$16,02590%
  • Education$2742%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,821 in reported general payments places this provider in the 80th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$365,508
Medicare patients
717
Services billed
2,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$191,023
EntrestoSacubitril/Valsartan63$76,575
JardianceEmpagliflozin42$32,070
Repatha SureclickEvolocumab17$11,495
XareltoRivaroxaban12$11,334
Ranolazine ErRanolazine35$4,423
Diltiazem 12hr ErDiltiazem Hcl13$3,255
Metoprolol Succinate165$2,436
Potassium Chloride40$890
Flecainide Acetate20$868
Atorvastatin Calcium97$723
Amiodarone Hcl13$693
Rosuvastatin Calcium38$643
Carvedilol68$517
Amlodipine Besylate110$494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$715$191,023150 claims
NovartisEntresto$1,226$76,57563 claims
Boehringer IngelheimJardiance$396$32,07042 claims
Johnson & JohnsonXarelto$316$11,33412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →